FEBS Letters
Volume 582, Issue 5 , Pages 611-615, 5 March 2008

Uteroglobin interacts with the heparin-binding site of fibronectin and prevents fibronectin–IgA complex formation found in IgA-nephropathy

Edited by Gianni Cesareni

Section on Developmental Genetics, Heritable Disorders Branch, NICHD, NIH, Bethesda, MD 20892-1830, United States

Received 17 December 2007; received in revised form 11 January 2008; accepted 17 January 2008. published online 01 February 2008.

Article Outline

Abstract 

Immunoglobulin A (IgA)-nephropathy (IgAN) is the most common primary renal glomerular disease in the world that has no effective treatment. High levels of circulating IgA–fibronectin (Fn) complexes, characteristically found in IgAN patients, are suggested to cause abnormal deposition of IgA and Fn in the renal glomeruli of these patients causing renal failure. We previously reported that binding of Fn to uteroglobin (UG), a multifunctional anti-inflammatory protein, inhibits Fn–IgA heteromerization. However, the specific site of Fn–UG interaction until now remained unidentified. We report here that UG interacts with the heparin-binding site of Fn and propose that small molecules competing for interaction with this site may reduce the level of circulating Fn–IgA complexes in IgAN.

Keywords: Uteroglobin, Clara cell 10kDa protein, Fibronectin, IgA-nephropathy

 

Back to Article Outline

1. Introduction 

Uteroglobin (UG), also known as Clara cell 10kDa (CC10) protein, is the founding member of a newly recognized superfamily of proteins called Secretoglobin [1]. It is a steroid-inducible, multifunctional, secreted protein with potent anti-inflammatory and anti-chemotactic properties [2]. We previously reported that UG-knockout (UG-KO) mice [3] develop abnormal deposition of immunoglobulin A (IgA) and fibronectin (Fn) in the renal glomeruli, reminiscent of the pathologic finding characteristic of human IgA-nephropathy (IgAN) [4]. IgAN is worldwide the most common primary glomerular disease that has no effective treatment [5]. It has been reported that in patients with IgAN high levels of circulating Fn–IgA complexes are found and these complexes are suggested to play critical roles in the abnormal deposition of IgA and Fn in the renal glomeruli leading to IgAN pathogenesis [6]. Consistent with this finding, we uncovered that in the UG-KO mice serum levels of Fn–IgA complexes are also present [4]. More importantly, we found that treatment of these mice with purified recombinant human UG (hUG) prevents abnormal glomerular deposition of Fn and IgA [4]. However, the specific site of Fn on which UG interacts and the molecular mechanism(s) by which UG suppresses the formation of Fn–IgA heteromers remain unclear.

Fibronectin (Fn) is a large adhesive glycoprotein composed of two nearly identical subunits of 220kDa (reviewed in [7], [8]). Each of these subunits contains a series of functional binding domains on which several proteins have been reported to interact [9]. Fn is essential for normal growth and development [10] and it plays critical roles in cell attachment, movement, wound healing and cancer (for review see [11]). Fn is detectable as a soluble glycoprotein in blood and other body fluids and an insoluble form constitutes a major extracellular matrix protein in tissues.

We previously reported that UG binds Fn and prevents abnormal glomerular deposition of Fn and IgA [4], a characteristic pathologic finding in human IgA-nephropathy (IgAN). We have also reported that UG binds Fn and most likely suppresses the formation of Fn–IgA heteromers [4]. However, the specific site on Fn with which UG interacts and prevents Fn–IgA heteromerizaton, until now, remained unclear. The identification of this site on Fn may yield valuable information for the development of small molecules that functionally mimic UG and prevent Fn–IgA heteromerization. Thus, this site may be a potential target for developing novel approaches to reduce the level of circulating Fn–IgA complexes in IgAN. Accordingly, we carried out experiments to identify and characterize the specific site(s) on Fn with which UG interacts forming Fn–UG heteromers.

Back to Article Outline

2. Materials and methods 

2.1. Reagents 

Fn and its peptide fragments were purchased from Sigma and Invitrogen, respectively. Purified secretory IgA from human colostrum and BSA were purchased from Sigma (St. Louis, MO). Labeling of recombinant human UG (hUG) was performed by Amersham Radiochemicals.

2.2. Radioiodination of recombinant IgA 

This purified IgA (25μg) was radioiodinated by using Na125I (2mCi; carrier free; 1Ci=37GBq) and Iodo-Beads. The reaction was carried out in 130μl of PBS; pH 7.4, at 25°C for 10min. 125I–IgA was purified by Sephdex G-25 spun-column chromatography (1200×g for 4min). The column was prewashed with 0.05% bovine serum albumin (BSA) in PBS. The specific activity of purified carrier-free 125I–human IgA was 20μCi/μmole.

2.3. Preparation of pure recombinant hUG and radiolabeled of hUG 

Recombinant hUG was expressed in Escherichia coli and purified to homogeneity as previously reported [12]. This protein (25μg) was radioiodinated using sodium [125I] (2mCi; carrier free; 1Ci=37GBq) and IODO-BEADS. The reaction was carried out in 130μl of phosphate-buffered saline (PBS; pH 7.4) at 25°C for 10min, and was [125I]-hUG was purified by Sephdex G-25 spun-column chromatography (1200×g for 4min). The column was pre washed with 0.05% bovine serum albumin (BSA) in PBS. The specific activity of purified carrier-free 125I–hUG was 25μCi/μmole.

2.4. Ligand affinity chromatography 

Fibronectin and its different fragments were purchased from Sigma and Gibco BRL for the preparation of fibronectin Sepharose affinity column. Fibronectin and its fragments were dialyzed overnight at 4°C against 0.1M NaHCO3 buffer, pH 8.3, containing 0.5M NaCl (coupling buffer). Fibronectin was then coupled to cyanogen bromide activated Sepharose-4-B (Pharmica Fine Chemicals, Piscataway, NJ) according to the manufacturer’s instructions. Briefly, fibronectin and its fragments were incubated overnight at 4°C with 0.3g cyanogen bromide-activated sepharose, which was pre-washed three times with 1mM HCl. Active groups were blocked with 0.2M glycine for 20h at 4°C. Excess ligand was removed by alternatively washing the resin with the coupling buffer and 0.1M Sodium Acetate buffer, pH 4.0, containing 0.5M NaCl. One hundred microliters of each mixture containing Fn or its fragments supported with Sepharose-4-B was incubated with 3H–hUG (2μCi) under physiological condition in binding buffer in Hanks’ balance salt solution (HBBS), pH 7.4 containing 0.1% bovine serum albumin in the presence and absence of excess unlabeled hUG at room temperature for 1h. The reaction was stopped by rapid removal of unbound 3H–hUG and the matrix was washed three times with PBS, pH 7.4. The radioactivity was taken with radioactive counter.

2.5. Binding of hUG and IgA with Fn affinity column 

Binding reactions of hUG or IgA with fibronectin and its fragments containing different binding domain in solution were carried out at room temperature by mixing 0.5–1.5 pmol of the 125I-ligand (hUG or IgA; 5–15×104cpm/pmol) with 50pmol biotinylated Fn and its fragments in 300μl of 50mM sodium phosphate, pH 7.4, containing 100mM NaCl (PBS) in the absence and presence of varying concentration of cold ligand during competition studies. After 30min of incubation, 1mg/ml bis(sulfosuccinimidyl) suberate (BS3; Pierce) was added in the reaction mixture and after another 30min of incubation, the cross-linker was inactivated by adding 30μl of 2M glycine, pH 7.4. at room temperature for 30min. Thereafter, 30μl of 40mM BSA was added. From each reaction vial, 300μl was transferred to a new vial containing 10μl of prepacked streptavidin-conjugated agarose beads (1.5mg streptavidin/ml; Pierce) and 50μl of packed Sepharose CL-4B (Pharmacia Biotech Inc.). The Sepharose and agarose beads were preblocked with 2mg/ml BSA in PBS to reduce the nonspecific binding. Binding to the beads was carried out at 4°C over night on an end-over-end rotator. The reaction was stopped by rapid removal of unbound radioactive material and the reaction bead was washed four times with PBS, pH 7.4 containing 0.05% Tween 20. The specific binding was calculated by subtracting the non specific binding from the total binding. The binding was analyzed by Scatchard plot using the Ligand computer program.

2.6. In vitro binding of hUG and Fn 

Binding studies using recombinant hUG and purified Fn binding were also carried out by incubating a mixture of 10nM purified [3H]-hUG (Amersham Radiochemicals) and Fn (100μg/ml) containing varying concentrations of unlabeled hUG (0–50nM) in 50mM sodium phosphate buffer containing150mM KCl, pH 7.5, was incubated for 60min at 4°C in the presence of 10mM of the crosslinking agen, DSS (Pierce). The reaction was stopped by adding 1M Tris–HCl, pH 6.8 to 1/10 the volume of the reaction mixture and the products were resolved electrophoresis using a 4–20% SDS gel followed by autoradiography using a Cyclone phosphorimager (Packard).

2.7. Statistical analysis 

Statistical analyses of the data were performed using Graph Pad Prism V4.0 software (Graph Pad Software Inc., San Diego, CA) and Minitab Version 13 (Minitab Inc., State College, PA). P-values ⩽0.05 were considered as statistically significant. All experiments were repeated three times.

Back to Article Outline

3. Results and discussion 

3.1. Recombinant human UG binds to the heparin-binding site of fibronectin 

Fibronectin consists of type I, type II and type III repeats, and the variable connecting sequence with several binding domains including those that specifically bind heparin- and gelatin. It has been reported that each of these binding domains has specific functional activity [13]. We first sought to identify and characterize the specific site(s) on Fn with which UG interacts. Accordingly, we first carried out binding studies using [3H] recombinant human UG (hUG) and synthetic peptides corresponding to various fragments of Fn containing the binding sites for heparin+gelatin (He+G), heparin (He) only or gelatin (G) only. The results show that recombinant hUG interacts with the Fn fragments that contain He+G and He-binding sites but does not interact with the Fn fragment containing G-binding site only (Fig. 1A). In order to determine which of the two sites [i.e. heparin-(He) or gelatin-(G) binding sites] specifically interacts with hUG in further detail, we carried out binding studies using Fn fragments, He+G and He by incubating each of these fragments with equal amounts of 3H–hUG followed by addition of increasing concentrations of non-radioactive hUG for competition. Our results show that 3H–UG bound to both Fn fragnments is displaced by unlabeled hUG in a dose-dependent manner (Fig. 1B). These results show that UG binds to the He-binding site of Fn with high specificity. To further confirm whether hUG specifically interacts with the He-binding site of Fn, we incubated a fixed concentrations Fn and 3H–hUG together with increasing concentrations of heparin in a competition assay. The results show that non-radioactive heparin displaces 3H–hUG bound to He containing fragment of Fn in a dose-dependent manner (Fig. 1C). These results strongly suggest that hUG specifically binds to the heparin-binding site of Fn.

  • View full-size image.
  • Fig. 1. 

    (A) Binding of hUG with Fn and its fragments containing different binding domain. One hundred microliters of mixtures containing Fn or its different fragments (Pharmica Fine Chemicals, Piscataway, NJ) containing each of the following binding sites: (He+G)-, (He)- or (G) were incubated with 3H–hUG (2μCi) in the binding buffer (Hanks’ Balance Salt Solution, pH 7.4 containing 0.1% bovine serum albumin) at the room temperature for 1h. The reaction was stopped by washing three times with 1× PBS, pH 7.4 to remove 3H–hUG. The data are presented as the mean (n=3 experiments)±S.D. (B) Binding of 3H–hUG with the Fn fragment containing (He+G) and (He) sites. Binding studies were performed as described with varying concentrations of unlabeled hUG (0–50nM) at room temperature for 1h. The data are presented as the mean (n=3 experiments)±S.D. (C) Binding specificity of hUG with the Fn fragment containing the (He)-binding site. Binding studies were carried out as described except that non-radioactive heparin in varying concentrations (0–50nM) were used for competition with 3H–hUG. The data are from three experiments, and each data point represents the mean of triplicate determinations. (D) Affinity crosslinking studies. Affinity crosslinking studies were carried out as described under Section 2. Binding and crosslinking of 3H–hUG–Fn or its fragments containing different binding domains are readily detectable. Lane 1: He+G; lane 2: He only; lane 3: 3H–hUG control; lane 4: Myoglobin (Myg) as a non-specific control for hUG. (E) Determination of specificity of 3H–hUG-binding to (He+G)-binding site of Fn. (He+G) containing fragment of Fn was incubated with a fixed concentration of 3H–hUG and competed with varying concentrations of non-radioactive hUG. Lane 1: control without non-radioactive hUG; lane 2: 2nM hUG; lane 3: 5nM hUG; lane 4: 10nM hUG; lane 5: 25nM hUG. (F) Non-specific binding of Fn fragment containing (G)-binding site only. Lane 1: Control without hUG, lane 2: 5nM hUG; lane 3: 10nM hUG; lane 4: 25nM hUG. (G.) Specificity of 3H–hUG binding with the (He)-binding site of Fn. Lane 1: 2nM hUG; lane 2: 5nM hUG; lane 3: 10nM hUG; lane 4: 25nM hUG; lane 5: 50nM hUG. (He)=Fn fragment containing the heparin binding site; (G)=Fn fragment containing the gelatin-binding site; hUG=human uteroglobin.

3.2. Binding of UG to the heparin-binding site of Fn is highly specific 

To further confirm the specificity of hUG binding to the heparin-binding site of Fn, we incubated total Fn or its fragments containing either He- or G-binding sites with a specific concentration of 3H–hUG together with increasing concentrations of non-radioactive hUG. The protein mixture was resolved by SDS–PAGE under non-denaturing and non-reducing conditions and radioactive protein bands were detected using a phosphorimager (Packard). The results show that radioactive hUG bound to Fn fragment containing He- or He+G-binding sites (Fig. 1D). Most importantly, non-radioactive hUG displaced 3H–hUG from the Fn fragment containing the He-binding site only in a dose-dependent manner (Fig. 1E), while it failed to displace radioactive hUG from the Fn-peptide that contained only the G-binding site (Fig. 1F). Taken together, these results demonstrate that hUG binds to the heparin-binding site of Fn with high specificity.

To gather further proof that the interaction of hUG with Fn indeed requires the heparin-binding site of Fn, we performed affinity-crosslinking studies using 3H–hUG and non-radioactive Fn as well as Fn-peptide fragment containing only the (He)-binding site in the presence or absence of varying concentrations of non-radioactive hUG. Disuccinimidylsuberate (DSS), a crosslinking agent, was added to the mixture. The protein mixture was resolved by SDS–PAGE under denaturing and reducing conditions and the radioactive protein bands were detected by using a phosphorimager. 3H–hUG bound to the Fn fragment containing the (He)-binding site and this binding is displaced by non-radioactive hUG in a dose-dependent manner (Fig. 1G, lanes 1–5).

3.3. Fibronectin binds to UG with higher affinity that IgA 

We previously reported that Fn–hUG interaction prevents Fn–IgA heteromerization, reported to be critical for abnormal accumulation of IgA in the renal glomeruli of IgAN patients [6] as well as in those of the UG-KO mice [4]. The results of our present study show that hUG specifically binds Fn with its carboxy-terminal heparin-binding domain but not with the gelatin binding site. Since hUG prevents Fn–IgA heteromerization, we sought to determine the affinities of Fn for binding to hUG and to IgA. Accordingly, we conducted binding studies using 125I–UG or 125I–IgA and non-radioactive Fn in presence of increasing concentrations of either non-radioactive hUG or IgA. The disassociation constants (Kds) for Fn binding to IgA and Fn binding to hUG were determined. The specific binding of 125I–UG to Fn was saturable (Fig. 2A) and specific. Further, the Scatchard analysis of these data show that there is a single high-affinity binding-site for hUG on Fn. The calculated apparent dissociation constant (Kd) for binding of hUG to Fn is 15nM (Fig. 2B). Similar experiments conducted with fixed concentration of 125I–IgA binding to Fn and increasing concentrations of unlabeled IgA show that binding of 125I–IgA to Fn is also saturable (Fig. 2C) with a dissociation constant (Kd) of 65nM (Fig. 2D). Taken together, these results raise the possibility that the high-affinity binding of hUG to Fn (Kd=15nM) is effective in preventing the Fn–IgA complex formation, reported to cause abnormal accumulation of IgA and Fn in renal glomeruli leading to IgAN.

  • View full-size image.
  • Fig. 2. 

    (A) Saturation isotherm and Scatchard analysis of 125 I–UG binding to Fn. Binding isotherms of hUG to Fn were performed by incubating increasing concentrations of 125I–UG. Specific binding (■) was calculated by subtracting nonspecific binding (▾), measured as the residual binding in the presence of hUG, from the total binding (■). The data shown are the mean of triplicate measurements±S.D. (B) Scatchard plots of hUG binding to Fn. The apparent dissociation constant (Kd) estimated from the slope of the line was 15nM±2.6nM (n=3). (C) Binding isotherms of IgA to Fn. Binding isotherms of IgA to Fn were performed by incubating increasing concentration of 125I–IgA. Specific binding (■) was calculated by subtracting nonspecific binding (▾), measured as the residual binding in the presence of IgA, from the total binding (■). The data shown are the mean of triplicate measurements. (D) Scatchard plots of IgA binding to Fn. The apparent dissociation constant (Kd) estimated from the slope of the line was 65nM±5.2nM (n=3).

Several regions of Fn are involved in supporting specific biological functions such as cell adhesion, spreading and migration. In addition, Fn is a major constituent of the extracellular matrix. In pathologic conditions such as IgAN, abnormal deposition of Fn and IgA in the renal glomeruli resulting from excessive circulating Fn–IgA heteromers appears critical for IgAN pathogenesis [6]. Thus, inhibition of Fn–IgA heteromerization may facilitate the development of novel therapeutic strategies for IgAN. In this study, we have demonstrated that the interaction of Fn with UG occurs on its heparin binding site. The identification of this UG binding site on Fn not only explains the molecular mechanism by which UG prevents abnormal deposition of IgA and Fn in the glomeruli but also demonstrate that this region of Fn is a potential target for the development of small molecules that prevent Fn–IgA heteromerization and prevent IgAN.

It has been reported that recombinant human UG prevents adhesion and migration of human endothelial cells in vitro by its specific interaction with fibronectin [14]. However, the specific region(s) of the Fn molecule with which UG interacts and exerts its biological functions until now remained undefined. From the perspective of IgAN, identification of this site may allow development of small molecules that competes for interaction with this site and prevents the formation of Fn–IgA heteromers reported to be associated with IgAN [6], [15]. There are three different repeating sequences in each Fn subunit, types I, II and III. Incorporation of dimeric Fn into extracellular matrix (ECM) requires consecutive binding interactions with itself, with integrin receptors, and with various components of the ECM such as type I collagen (reviewed in [16], [17]). There are also two heparin binding sites (Hep I and Hep II) in the amino- and carboxy terminal, respectively, of Fn. The heparin-binding domain at the COOH-terminal of Fn binds CD44 [18], a high affinity receptor for hyaluronan [19]. Amino-terminal heparin binding fragments of Fn stimulates proteoglycan breakdown [19] and release catabolic cytokines [20]. It has been reported that the 40kDa COOH-terminal heparin-binding fragment of Fn binds to CD44 and regulates MMP gene expression [21]. By competing with CD44 for interaction with the heparin-binding site of Fn, hUG may prevent the release the cytokines that are proinflammatory and help to maintain homeostasis. This may be another mechanism by which UG exerts its anti-inflammatory effects [2].

In summary, we have identified the specific site on the Fn molecule with which UG interacts and suppresses the formation of Fn–IgA complexes, which are found at a high level in the circulation of IgAN patients and thought to contribute of abnormal deposition of IgA and Fn in the renal glomeruli of the IgAN patients leading to renal failure. Thus, our results identify a potential drug target for IgAN.

Back to Article Outline

Acknowledgement 

We thank Drs. J.Y. Chou and I. Owens for critical review of the manuscript and helpful suggestions. This research was supported in full by the intramural NICHD, NIH.

Back to Article Outline

References 

  1. Mukherjee, A.B. and Chilton, B.S. (Eds.) (2000) The uteroglobin/Clara cell protein family. Nomenclature Committee Report. Ann. N.Y. Acad. Sci. 293, 348–356.
  2. Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a steroid- inducible immunomodulatory protein that founded the secretoglobin superfamily. Endocrine Rev. 2007;28:707–725
  3. Zhang Z, Kundu GC, Yuan CJ, Ward JM, Lee EJ, DeMayo F, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science. 1997;276:1408–1412
  4. Zheng F, Kundu GC, Zhang Z, Ward J, DeMayo F, Mukherjee AB. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat. Med. 1999;5:1018–1025
  5. Hsu SI. The molecular pathogenesis and experimental therapy of IgA nephropathy: recent advances and future directions. Curr. Mol. Med. 2001;1:183–196
  6. Cederholm B, Wieslander J, Bygren P, Heinegard D. Circulating complexes containing IgA and fibronectin in patients with primary IgA nephropathy. Proc. Natl. Acad. Sci. USA. 1988;85:4865–4868
  7. Hynes RO. Fibronectins: a family of complex and versatile adhesive glycoproteins derived from a single gene. Harvey Lect. 1985-1986;81:133–152
  8. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 1999;76:1–20
  9. Pankov R, Yamada KM. Fibronectin at a glance. J. Cell Sci. 2002;115:3861–3863
  10. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993;119:1079–1091
  11. Hynes RO, Schwarzbauer JE, Tamkun JW. Fibronectin: a versatile gene for a versatile protein. Ciba Found Symp. 1984;108:75–92
  12. Mantile G, Miele L, Cordella-Miele E, Singh G, Katyal SL, Mukherjee AB. Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin. J. Biol. Chem. 1993;268:20343–20351
  13. Hayashi M, Schlesinger DH, Kennedy DW, Yamada KM. Isolation and characterization of a heparin-binding domain of cellular fibronectin. J. Biol. Chem. 1980;255:10017–10020
  14. Antico G, Lingen MW, Sassano A, Melby J, Welch RW, Fiore S, et al. Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin. J. Cell Physiol. 2006;207:553–561
  15. Coppo R, Amore A, Gianoglio B, Porcellini MG, Peruzzi L, Gusmano R, et al Macromolecular IgA and abnormal IgA reactivity in sera from children with IgA nephropathy. Italian collaborative paediatric IgA nephropathy study. Clin. Nephrol. 1995;43:1–13
  16. Mosher DF. Assembly of fibronectin into extracellular matrix. Curr. Opin. Struct. Biol. 1993;3:214–222
  17. Schwartz MA, Schaller MD, Ginnsberg MH. Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell. Dev. Biol. 1995;11:549–599
  18. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol. 1992;116:817–825
  19. Aruffo A, Stamenkovic I, Melnick M, Uderhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1303–1313
  20. Yasuda T, Poole AR. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum. 2002;4:138–148
  21. Yasuda T, Poole AR, Shimizu M, Nakagawa T, Julovi SM, Tamamura H, et al. Involvement of CD44 in induction of matrix metalloproteinases by a COOH-terminal heparin-binding fragment of fibronectin in human articular cartilage in culture. Arthritis Rheum. 2003;48:1271–1280

PII: S0014-5793(08)00050-1

doi:10.1016/j.febslet.2008.01.025

FEBS Letters
Volume 582, Issue 5 , Pages 611-615, 5 March 2008

Article Tools

* Image Usage & Resolution